Avinger, Inc. (AVGR)
| Market Cap | 179.28M |
| Revenue (ttm) | 8.59M |
| Net Income (ttm) | -23.29M |
| Shares Out | 69.46M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $2.09 |
| Previous Close | $2.30 |
| Change ($) | -0.21 |
| Change (%) | -9.13% |
| Day's Open | 2.16 |
| Day's Range | 2.05 - 2.21 |
| Day's Volume | 17,094,608 |
| 52-Week Range | 0.22 - 2.30 |
19 New U.S. and International Patents Issued and Allowed in 2020 REDWOOD CITY, CA / ACCESSWIRE / January 19, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marke...
Avinger (AVGR) stock is taking off on Friday after announcing the full commercial release of its Tigereye medical device. The post AVGR Stock: 11 Things to Know About Avinger as Shares Rocket ...
REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-base...
Avinger (AVGR) is seeing a massive boost to its stock on Friday after being listed as a hot penny stock to buy on Robinhood. The post AVGR Stock: 6 Things to Know About ‘Robinhood's Hot Penny ...
REDWOOD CITY, CA / ACCESSWIRE / January 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the di...
REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the ...
Avinger's (AVGR) CEO Jeff Soinski on Q3 2020 Results - Earnings Call Transcript
Avinger (AVGR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avinger (AVGR) news for Friday concerning approval from the FDA for one of its medical devices has AVGR stock on the move. The post Avinger News: AVGR Stock Down 8% Following FDA Approval appe...
Avinger's (AVGR) CEO Jeff Soinski on Q2 2020 Results - Earnings Call Transcript
Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
There are pockets of the stock market that look far too overvalued to ignore, and our deep learning algorithms paired with our Artificial Intelligence (“AI”) technology has identified the top ...
Avinger (AVGR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2020 Results - Earnings Call Transcript
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Bet on these top-ranked stocks with rising P/E for outsized gains.
Avinger, Inc. (AVGR) CEO Jeffrey Soinski on Q3 2019 Results - Earnings Call Transcript
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for October 24th
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the clo...
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pr...
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that i...
Avinger's (AVGR) CEO Jeff Soinski on Q2 2019 Results - Earnings Call Transcript
Is (AVGR) Outperforming Other Medical Stocks This Year?
Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2019 Results - Earnings Call Transcript
Is (AVGR) Outperforming Other Medical Stocks This Year?
Avinger (AVGR) closed at $0.58 in the latest trading session, marking a -0.62% move from the prior day.
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 9th.
About AVGR
Avinger, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family o... [Read more...]
| Industry Medical Devices | IPO Date Jan 30, 2015 |
| CEO Jeffrey Soinski | Employees 74 |
| Stock Exchange NASDAQ | Ticker Symbol AVGR |
Financial Performance
In 2019, Avinger's revenue was $9.13 million, an increase of 15.36% compared to the previous year's $7.92 million. Losses were -$19.45 million, -29.42% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for Avinger stock is "Buy." The 12-month stock price forecast is 2.50, which is an increase of 19.62% from the latest price.